Philippines Pharmaceuticals and Healthcare Report Q3 2014

132 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Medicine pricing controls will continue to limit the growth potential of the Philippine
pharmaceutical market. However, over the longer term progressive implementation of universal healthcare
coverage, coupled with the country’s relatively strong economic growth and political stability, will boost
pharmaceutical consumption.
Headline Expenditure Projections
? Pharmaceuticals: PHP138.45bn (USD3.20bn) in 2013, rising to PHP143.55bn (USD3.26bn) in 2014;
+3.7% in local currency terms and +1.8% in US dollar terms.
? Healthcare: PHP545.09bn (USD12.62bn) in 2013, rising to PHP611.29bn (USD13.89bn) in 2014;
+12.1% in local currency terms and +10.1% in US dollar terms.

Table Of Contents

BMI Industry View 7
SWOT 9
Political 11
Economic 12
Business Environment 13
Industry Forecast 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Philippines 2010-2018) 16
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Philippines 2010-2018) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Philippines 2012-2018) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Philippines 2012-2018) 32
Other Healthcare Data 33
Key Risks To BMI's Forecast Scenario 34
Macroeconomic Forecasts 35
Economic Analysis 35
Investment To Continue Its Charge 35
Likely Recovery In The Export Sector 37
Typhoon Yolanda To Spur Public Spending 38
Remittances Supporting Private Consumption Growth 38
Risks To Economic Outlook 39
Table: Philippines - Economic Activity 40
Industry Risk Reward Ratings 41
Asia Risk/Reward Ratings 41
Philippines Risk/Reward Ratings 47
Rewards 47
Risks 47
Market Overview 49
Industry Trends And Developments 50
Epidemiology 50
Healthcare Sector 54
Health Insurance 58
Healthcare Sector Financing 61
Medical Tourism 61
Biotechnology And Research 62
Traditional Medicines 64
Clinical Trials 65
Regulatory Development 66
Table: History Of Food And Drugs Administration 67
Intellectual Property Regime 70
Pricing Regime 75
Table: Medicines Subject To March 31 2010 Government Mediated Access Price 79
Reimbursement Regime 80
International Cooperation 81
Competitive Landscape 84
Pharmaceutical Industry 84
Table: Pharmaceutical Industry Overview 84
Domestic Pharmaceutical Industry 84
Pharmaceutical Distribution and Retail 87
Table: Overview Of BnB, BNB and P100 Programme 92
Table: Cost Of Generic Drugs In Philippines (PHP) 92
Table: Number Of BnBs And BNBs In Selected Philippine Regions 93
Company Profile 94
Unilab 94
Pascual Laboratories 97
Pacific Pharmaceutical Generics 100
MediChem Pharmaceuticals 102
GlaxoSmithKline Philippines 104
Pfizer 107
Novartis 111
Merck & Co 116
Sanofi 118
Demographic Forecast 122
Demographic Outlook 122
Table: The Philippines' Population By Age Group, 1990-2020 ('000) 123
Table: The Philippines' Population By Age Group, 1990-2020 (% of total) 124
Table: The Philippines' Key Population Ratios, 1990-2020 125
Table: The Philippines' Rural And Urban Population, 1990-2020 125
Glossary 126
Methodology 128
Pharmaceutical Expenditure Forecast Model 128
Healthcare Expenditure Forecast Model 128
Notes On Methodology 129
Risk/Reward Ratings Methodology 130
Ratings Overview 131
Table: Pharmaceutical Risk/Reward Ratings Indicators 131
Indicator Weightings 132

List Of Tables

Table: Pharmaceutical Sales, Historical Data And Forecasts (Philippines 2010-2018)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Philippines 2010-2018)
Table: Pharmaceutical Trade Data And Forecasts (Philippines 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Philippines 2012-2018)
Table: Philippines - Economic Activity
Table: History Of Food And Drugs Administration
Table: Medicines Subject To March 31 2010 Government Mediated Access Price
Table: Pharmaceutical Industry Overview
Table: Overview Of BnB, BNB and P100 Programme
Table: Cost Of Generic Drugs In Philippines (PHP)
Table: Number Of BnBs And BNBs In Selected Philippine Regions
Table: The Philippines' Population By Age Group, 1990-2020 ('000)
Table: The Philippines' Population By Age Group, 1990-2020 (% of total)
Table: The Philippines' Key Population Ratios, 1990-2020
Table: The Philippines' Rural And Urban Population, 1990-2020
Table: Pharmaceutical Risk/Reward Ratings Indicators

Related Reports

  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Egypt Pharmaceuticals and Healthcare Report Q1 2015BMI View: Recent developments have led us to hold a more positive outlook for Egypt's pharmaceutical and healthcare markets. An increased healthcare budget for 2015, combined with the government's efforts at developing the local manufacturing industry and combating medicine shortages and counterfeit drugs are all positive developments. We expect Egypt's relative political stability and positive economic outlook to further increase interest from foreign pharmaceutical […]
  • Tanzania Pharmaceuticals and Healthcare Report Q4 2015BMI View: Tanzania's pharmaceutical sector will continue to be dominated by generic drugmakers, largely those from India. Although government encouragement of domestic pharmaceutical production will increase domestic output, the majority of the country's pharmaceutical needs will remain sourced from abroad. Headline Expenditure Projections ? Pharmaceuticals: TZS797bn (USD479mn) in 2014 to an expected TZS909bn (USD496mn) in 2015; +14.0% growth in local currency terms and +3.5% in US […]
  • Saudi Arabia Pharmaceuticals and Healthcare Report Q2 2014BMI View: We hold a very positive outlook towards growth in the Saudi Arabian medicines market over the next decade, with pharmaceutical demand underpinned by a number of factors. However, risks to our outlook are to the downside, some of which include greater-than-expected drops in the oil price, the government's failure to deliver on healthcare infrastructure expansion and medicine price cuts in the short term. Headline Expenditure Projections ? Pharmaceuticals: SAR22.7bn […]
  • Philippines Pharmaceuticals and Healthcare Report Q2 2016BMI View: The relative distribution of diseases in the Philippines will remain favourable for multinational drugmakers. Chronic conditions such as cancer, cardiovascular disease and diabetes will drive demand for healthcare services and medicines. Access to medicines will be strengthened by the continued expansion of universal healthcare in the country. However, price caps on high-value medicines and poor intellectual property protection continue to limit commercial opportunities for […]